FindTrial
Sign In

Predicting residual disease in cancer ovary with tumour markers

Preoperative prediction of residual disease in patients with advanced ovarian malignancy using HE4 and CA 125

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/12/029922
Enrollment
50
Registered
2020-12-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C562- Malignant neoplasm of left ovary Health Condition 2: C561- Malignant neoplasm of right ovary Health Condition 3: C569- Malignant neoplasm of unspecifiedovary

Interventions

Intervention1: NIL: NIL

Sponsors

Dr Rajlaxmi Mundhra
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients of epithelial ovarian malignancy planned for primary or interval debulking surgery and those who gives consent to participate in the study.

Exclusion criteria

Exclusion criteria: concomitant treatment for multiple types of primary cancer and decreased kidney function (glomerular filtration rate <60 mL/min/1.73 m2) since this significantly impacts the concentration of HE4.

Design outcomes

Primary

MeasureTime frame
To find out cut off values for CA125 & He4 in relation to optimal cytoreduction for advanced epithelial ovarian malignancy in both primary and interval debulking surgery in our settings.Timepoint: baseline—

Secondary

MeasureTime frame
N/ATimepoint: N/A—

Countries

India

Contacts

Public ContactDr Rajlaxmi Mundhra

AIIMS Rishikesh

rmundhra54@yahoo.com8057482137

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026